KR20010081116A - 트리사이클릭 파르네실 단백질 트랜스퍼라제 억제제 - Google Patents

트리사이클릭 파르네실 단백질 트랜스퍼라제 억제제 Download PDF

Info

Publication number
KR20010081116A
KR20010081116A KR1020017007632A KR20017007632A KR20010081116A KR 20010081116 A KR20010081116 A KR 20010081116A KR 1020017007632 A KR1020017007632 A KR 1020017007632A KR 20017007632 A KR20017007632 A KR 20017007632A KR 20010081116 A KR20010081116 A KR 20010081116A
Authority
KR
South Korea
Prior art keywords
alkyl
substituted
aryl
cycloalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020017007632A
Other languages
English (en)
Korean (ko)
Inventor
타베라스아써지.
돌로날드제이.
쿠퍼알랜비.
페레이라요한에이.
구지티모시
맬람스알랜케이.
레인디나나쓰에프.
기리자발라반비요르엠.
아폰소아드리아노
아키신씨아제이.
챠오지안핑
알바레즈카르멘
켈리죠셉엠.
랄와니타리크
데사이잭디쉬에이.
왕제임스제이.에스.
와인스타인제이
Original Assignee
둘락 노먼 씨.
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 둘락 노먼 씨., 쉐링 코포레이션 filed Critical 둘락 노먼 씨.
Publication of KR20010081116A publication Critical patent/KR20010081116A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020017007632A 1998-12-18 1999-12-16 트리사이클릭 파르네실 단백질 트랜스퍼라제 억제제 Abandoned KR20010081116A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21639898A 1998-12-18 1998-12-18
US09/216,398 1998-12-18
PCT/US1999/027939 WO2000037459A1 (en) 1998-12-18 1999-12-16 Tricyclic farnesyl protein transferase inhibitors

Publications (1)

Publication Number Publication Date
KR20010081116A true KR20010081116A (ko) 2001-08-27

Family

ID=22806914

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017007632A Abandoned KR20010081116A (ko) 1998-12-18 1999-12-16 트리사이클릭 파르네실 단백질 트랜스퍼라제 억제제

Country Status (20)

Country Link
EP (1) EP1140902A1 (cg-RX-API-DMAC7.html)
JP (1) JP2002533336A (cg-RX-API-DMAC7.html)
KR (1) KR20010081116A (cg-RX-API-DMAC7.html)
CN (1) CN1326850C (cg-RX-API-DMAC7.html)
AR (1) AR021718A1 (cg-RX-API-DMAC7.html)
AU (1) AU776558B2 (cg-RX-API-DMAC7.html)
BR (1) BR9916314A (cg-RX-API-DMAC7.html)
CA (1) CA2354779A1 (cg-RX-API-DMAC7.html)
CO (1) CO5160350A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20011950A3 (cg-RX-API-DMAC7.html)
HU (1) HUP0202152A2 (cg-RX-API-DMAC7.html)
IL (1) IL143408A0 (cg-RX-API-DMAC7.html)
NO (1) NO20012961L (cg-RX-API-DMAC7.html)
NZ (1) NZ511878A (cg-RX-API-DMAC7.html)
PE (1) PE20001342A1 (cg-RX-API-DMAC7.html)
PL (1) PL348293A1 (cg-RX-API-DMAC7.html)
SK (1) SK7592001A3 (cg-RX-API-DMAC7.html)
TR (1) TR200101755T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000037459A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200104233B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160134672A (ko) * 2014-03-19 2016-11-23 비아멧 파마슈티컬즈, 인코포레이티드 2-(2,4-디플루오로페닐)-1,1-디플루오로-1-(5-치환된-피리딘-2-일)-3-(1h-테트라졸-1-일)프로판-2-올 및 이의 제조방법

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002533336A (ja) 1998-12-18 2002-10-08 シェーリング コーポレイション 三環式ファルネシルタンパク質トランスフェラーゼインヒビター
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
AU2002236813A1 (en) 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002080895A2 (en) * 2001-04-06 2002-10-17 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
CN101115486A (zh) 2004-12-13 2008-01-30 先灵公司 新的法呢基蛋白转移酶抑制剂及其治疗癌症的用途
CN101128202A (zh) 2004-12-14 2008-02-20 先灵公司 法呢基蛋白质转移酶抑制剂和用于治疗增殖性疾病的方法
WO2007084498A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
CN109678791B (zh) 2014-03-19 2022-07-01 美国陶氏益农公司 1-(2,4-二氟苯)-2,2-二氟-2-(5-取代吡啶-2-基)乙酮及制备方法
JP7751894B2 (ja) * 2021-03-30 2025-10-09 ナミックス株式会社 硬化触媒、樹脂組成物、封止材、接着剤、及び硬化物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
ATE273299T1 (de) 1997-06-17 2004-08-15 Schering Corp Benzpyrido cycloheptan derivate mit farnesyl protein transferase inhibierender wirkung
JP2002533336A (ja) 1998-12-18 2002-10-08 シェーリング コーポレイション 三環式ファルネシルタンパク質トランスフェラーゼインヒビター

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160134672A (ko) * 2014-03-19 2016-11-23 비아멧 파마슈티컬즈, 인코포레이티드 2-(2,4-디플루오로페닐)-1,1-디플루오로-1-(5-치환된-피리딘-2-일)-3-(1h-테트라졸-1-일)프로판-2-올 및 이의 제조방법

Also Published As

Publication number Publication date
PE20001342A1 (es) 2000-12-09
SK7592001A3 (en) 2002-03-05
CA2354779A1 (en) 2000-06-29
NO20012961D0 (no) 2001-06-15
BR9916314A (pt) 2001-10-02
TR200101755T2 (tr) 2001-09-21
CO5160350A1 (es) 2002-05-30
CN1326850C (zh) 2007-07-18
AU2030700A (en) 2000-07-12
PL348293A1 (en) 2002-05-20
ZA200104233B (en) 2002-08-22
AR021718A1 (es) 2002-07-31
IL143408A0 (en) 2002-04-21
EP1140902A1 (en) 2001-10-10
WO2000037459A1 (en) 2000-06-29
CN1334811A (zh) 2002-02-06
JP2002533336A (ja) 2002-10-08
CZ20011950A3 (cs) 2001-12-12
NO20012961L (no) 2001-08-16
NZ511878A (en) 2003-10-31
HUP0202152A2 (en) 2002-10-28
AU776558B2 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
US6372747B1 (en) Farnesyl protein transferase inhibitors
US5712280A (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5880128A (en) Carbonyl piperazinyl and piperidinyl compounds
US6300338B1 (en) Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5891872A (en) Tricyclic compounds
US6492381B1 (en) Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
KR20010081115A (ko) 파르네실 단백질 트랜스퍼라제 억제제
EP1841758B1 (en) Substituted triazole derivatives as oxytocin antagonists
EP1716135B1 (en) Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
RU2293734C2 (ru) Трициклические противоопухолевые соединения, фармацевтическая композиция и способ лечения на их основе
EP0989983B1 (en) Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
CN1326850C (zh) 三环类法尼基蛋白转移酶抑制剂
KR20040098004A (ko) 항종양제로서의 파르네실 단백질 트랜스퍼라제 억제제
KR19990067622A (ko) 알레르기성 질환의 치료에 유용한 치환된 4-(1h-벤즈이미다졸-2-일-아미노)피페리딘
KR20000036103A (ko) 파르네실 단백질 트랜스퍼라제의 억제에 유용한 치환된벤조사이클로헵타피리딘 유도체
CN114315805A (zh) 芳环并环状内脂类硫代乙内酰脲化合物及制备方法和用途
JPH10182459A (ja) cGMP分解酵素阻害剤
MXPA01006241A (en) Tricyclic farnesyl protein transferase inhibitors
SK33299A3 (en) Tricyclic compounds useful for inhibition of farnesyl protein transferase
AU7815298A (en) Benzo(5,6)cyclohepta(1,2B)pyridine derivatives useful for inhibition of farnesyl protein transferase

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20010616

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20041215

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060428

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20070612

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee